Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis
A.M. Zicari, C. Celani, G. De Castro, R. Valerio De Biase, M. Duse Department of Pediatrics, Sapienza University of Rome, Rome, Italy. marzia.duse@gmail.com
Allergic bronchopulmonary aspergillosis (ABPA) occurs in 7-9% of patients with cystic fibrosis (CF) and causes a worsening of lung function and respiratory symptoms. Standard treatment of ABPA consists of oral steroids; however, higher corticosteroid therapy associated to antifungal agent (itraconazole) long-term treatments are often required to reduce respiratory exacerbations and to prevent progressive lung damage. Here we describe the case of a girl with CF who experienced clinical and functional improvement over 12-months treatment with omalizumab. At birth, our patient was diagnosed with mild-to-moderate CF and from childhood she underwent annual cycles of antibiotic and corticosteroid therapies. At 12 years, she presented with a worsening respiratory condition, asthma symptoms and reduced lung function (FEV1 of 78%). Blood tests showed an increased concentration of plasma total IgE and positive specific IgE antibodies to Aspergillus fumigatus; allergic skin tests were also positive for A. fumigatus. The patient started steroid therapy but had impaired glucose tolerance due to long-term steroid use. Subcutaneous omalizumab 300 mg every two weeks was initiated and after 14 weeks she had improved respiratory symptoms (FEV1 99%) and a marked reduction in the use of systemic antibiotic and corticosteroid therapies. No side effects were reported. Our case shows that therapy with omalizumab for a prolonged period can resolve symptoms of asthma.
Free PDF Download![Creative Commons License](https://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
A.M. Zicari, C. Celani, G. De Castro, R. Valerio De Biase, M. Duse
Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis
Eur Rev Med Pharmacol Sci
Year: 2014
Vol. 18 - N. 13
Pages: 1839-1841